CORT - Mid-Cap Corcept Therapeutics Reveals Data From Hormonal Disorder Study FDA Application Submission Expected This Quarter | Benzinga
Monday, Corcept Therapeutics Incorporated (NASDAQ:CORT) released results from the open-label portion of the pivotal Phase 3 GRACE trial of its proprietary selective cortisol modulator relacorilant in patients with all etiologies of endogenous Cushing’s syndrome (hypercortisolism).
GRACE has two parts.
- In the “open-label” phase, 152 patients with Cushing’s syndrome and either hypertension, hyperglycemia, or both received relacorilant for 22 weeks.
- Patients who exhibited pre-specified improvements in either or both symptoms could enter the trial’s withdrawal phase.
No cases of relacorilant-induced endometrial hypertrophy with or without vaginal bleeding were seen, nor were there any instances of adrenal insufficiency or QT prolongation.
Rapid and sustained improvements in systolic blood pressure (SBP) and diastolic blood pressure (DBP) were observed in ...